MarginsXMarginsX
Home › Markets › Health Care › COR

Cencora Inc. (COR)

COR trades on NYSE in Health Care, Other Pharmaceuticals. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$356.94
-0.58% on the day
Market cap
$68.1B
Large cap
Revenue · 2025
$321.3B
+9.3% on 2024
Net income · 2025
$1.6B
0.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-09-30, https://www.sec.gov/Archives/edgar/data/1140859/000114085925000131/0001140859-25-000131-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-09-30.

Profile

FieldValue
TickerCOR on NYSE
SectorHealth Care
IndustryOther Pharmaceuticals
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001140859
SEC industry codeWholesale-Drugs, Proprietaries & Druggists' Sundries
Incorporated inDE

Financials · 2025

LineValue
Revenue$321.3B
Net income$1.6B
Operating income$2.6B
Net margin0.5%
Operating margin0.8%
Revenue growth+9.3%
Cash$4.4B
Total assets$76.6B
P/E (computed)43.8×
P/S (computed)0.2×

Warning signs

Cash runway
Cash-flow positive
$2.8B cash at June 30, 2026
Share count, 1 year
-1.6%
2025-07-31 to 2026-07-31 · -5.6% over 3 years
Going-concern doubt
No
10-Q filed August 5, 2026
Insider net buying, 12 months
-$14.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-08-05
Cash and burn$2.8B cash; operating cash flow $1.2B a quarter.Report 2026-06-30
Shares outstanding190,827,165 (2026-07-31); 193,877,881 a year earlier; 202,174,856 three years earlier.Cover page 2026-07-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedownsLatest 2026-02-10
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Philadelphia, Pennsylvania, United StatesPCAOB Form AP 2026-02-16
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $2.3M, sold $17.0M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-06-30
$84.8B$763.5M$2.7B$2.8B$11.7B$332.8B10-Q 2026-08-05
Q2 2026
2026-03-31
$78.4B$1.6B$1.3B$2.2B$12.4B$328.7B10-Q 2026-05-06
Q1 2026
2025-12-31
$85.9B$559.6M-$2.3B$1.8B$7.9B$325.8B10-Q 2026-02-04
Q4 2025
2025-09-30
$83.7B-$339.7M$3.1B$4.4B$7.7B$321.3B10-K 2025-11-25
Q3 2025
2025-06-30
$80.7B$687.4M$109.2M$2.2B$8.2B$316.7B10-Q 2026-08-05
Q2 2025
2025-03-31
$75.5B$717.9M$3.4B$2.0B$7.9B$310.2B10-Q 2026-05-06
Q1 2025
2024-12-31
$81.5B$488.6M-$2.7B$3.2B$8.1B$303.2B10-Q 2026-02-04
Q4 2024
2024-09-30
$79.1B$3.4M$1.0B$3.1B$4.4B$294.0B10-K 2025-11-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B22026-02-11
Latest annual report10-K2025-11-25
Latest quarterly / interim10-Q2026-08-05
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-01-22

Source: SEC EDGAR submissions feed, 1,009 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+7.6%
1 month+8.8%
3 months+15.8%
Year to date+6.3%
1 year-1.8%
From 52-week high-4.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Other Pharmaceuticals

TickerCompanyPriceDayMarket cap
CAHCardinal Health Inc.$283.85+0.98%$65.6B
MCKMcKesson Corporation$1105.04+0.20%$127.6B
HLFHerbalife Ltd. Common Shares$16.15+1.19%$1.7B
COSMCosmos Health Inc.$2.49-23.15%$250.6M
NUSNu Skin Enterprises Inc.$3.93-2.48%$191.3M
ZSTKZeroStack Corp.$2.80-1.75%$61.1M
ESYNEnerSyn Global Inc.$1.250.00%$37.2M
HKPDCellyan Biotechnology Co. Ltd$1.61-0.62%$4.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier